Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread to nearby tissue or lymph nodes (locally advanced). Androgen ablation therapy (also known as hormone therapy) lowers the levels of male hormones called androgens in the body. Androgens stimulate prostate cancer cells to grow. There are 2 types of androgen ablation therapy given in this study: AAP + ADT and Apa + ADT. AAP + ADT is the treatment

Trial Details

NCT ID

NCT04947254

Phase

PHASE2

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Abiraterone Acetate
Antiandrogen Therapy
Apalutamide
Biopsy
Niraparib
Prednisone

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Completion of informed consent prior to any study specific procedures. Consent may be done remotely.
Patients must agree to tissue collection for correlative studies at the specified timepoints
Male aged 18 years and above
Histologically or cytologically confirmed prostate carcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →